Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. MGX
MGX logo

MGX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.510
Open
1.470
VWAP
1.50
Vol
48.07K
Mkt Cap
55.68M
Low
1.470
Amount
71.94K
EV/EBITDA(TTM)
--
Total Shares
37.62M
EV
-105.12M
EV/OCF(TTM)
--
P/S(TTM)
2.19
Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. It is developed to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. It focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. MGX-001, its lead, wholly owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. MGX-001 is designed to insert a Factor VIII (FVIII) DNA cassette into a safe harbor location within an intron of the albumin gene.
Show More

Events Timeline

(ET)
2026-01-12
08:40:00
MGX-001 Shows Curative Potential, IND Submission Expected in 2026
select
2025-11-11 (ET)
2025-11-11
16:10:40
Metagenomi CEO Brian Thomas to Step Down, Jian Irish to Take Over
select
2025-11-11
16:09:12
Metagenomi cuts its workforce by 25%
select
2025-11-11
16:07:22
Metagenomi Announces New Dose Range Findings for MGX-001 in Hemophilia A Program
select
2025-11-11
16:05:07
Metagenomi announces Q3 earnings per share of 55 cents, surpassing consensus estimate of 53 cents.
select
2025-10-27 (ET)
2025-10-27
13:53:13
Video: This Stock is Weighing Down the In Vivo Gene Editing Therapy Sector
select
link
2025-09-10 (ET)
2025-09-10
09:15:30
AbCellera Names Sarah Noonberg as Chief Medical Officer
select

News

seekingalpha
9.5
03-05seekingalpha
Metagenomi Reports FY Earnings with Significant Revenue Decline
  • Earnings Report: Metagenomi's FY GAAP EPS stands at -$2.36, aligning with market expectations, yet the overall performance fails to boost investor confidence amid challenging market conditions.
  • Revenue Decline: The company reported revenue of $25.2 million, reflecting a significant 51.8% year-over-year decline, missing the market estimate of $28.43 million, indicating severe operational challenges.
  • Market Reaction: The revenue miss is likely to negatively impact Metagenomi's stock price, as investor confidence in the company's future growth potential diminishes in light of disappointing financial results.
  • Industry Context: With increasing competition in the health tech sector, Metagenomi must implement effective strategies to restore growth and enhance its market share to navigate these turbulent times.
Globenewswire
8.5
01-12Globenewswire
Metagenomi Therapeutics Renames Company, Plans IND Submission for MGX-001 in 2026
  • Strategic Evolution: Metagenomi Therapeutics has changed its name to reflect its strategic focus on late-stage preclinical assets, aiming to leverage its advanced gene-editing capabilities to drive the success of therapeutic programs, particularly in hemophilia A.
  • Clinical Advancement: MGX-001 has demonstrated curative FVIII activity in non-human primates with no identifiable off-target editing, with plans to submit IND/CTA in Q4 2026 and initiate first-in-human studies in 2027.
  • Cash Runway: The company anticipates a cash runway extending through Q4 2027, ensuring financial stability while advancing MGX-001 and other therapeutic projects, thereby enhancing investor confidence.
  • Pipeline Prioritization: Through strategic pipeline prioritization, Metagenomi is focusing on MGX-001 and other potential therapies, showcasing its strong competitiveness and market potential in the gene therapy sector.
Newsfilter
8.5
01-12Newsfilter
Metagenomi Therapeutics Renames to Reflect Focus on Gene Therapy, MGX-001 IND Submission Planned for 2026
  • Strategic Evolution: Metagenomi Therapeutics has changed its name to reflect its strategic evolution focused on late-stage preclinical assets, particularly the MGX-001 program for hemophilia A, which is expected to submit IND/CTA in 2026, marking a significant advancement in gene therapy.
  • Clinical Readiness: MGX-001 demonstrated curative FVIII activity in non-human primates with no identifiable off-target editing, supporting its potential as a best-in-class treatment, with plans to initiate first-in-human studies in 2027 to further advance clinical development.
  • Cash Runway: The company anticipates a cash runway extending through Q4 2027, ensuring sufficient funding to support the advancement of MGX-001 and other therapeutic projects, thereby enhancing its competitive position in the market.
  • Pipeline Prioritization: Through strategic pipeline prioritization, Metagenomi is focusing on MGX-001 and other secreted protein deficiencies, showcasing the company's strong technological capabilities and promising market outlook in the field of gene editing.
NASDAQ.COM
2.0
2025-12-09NASDAQ.COM
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
  • Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.

  • Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.

  • Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.

  • Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.

WSJ
3.5
2025-12-02WSJ
Amazon's Custom Chips Present a New Challenge for Nvidia
  • Amazon's New AI Chip: Amazon Web Services has launched its Trainium3 custom AI chip, which is claimed to be four times faster than its previous AI chips.

  • Cost Efficiency: The Trainium3 chip can potentially reduce the costs of training and operating AI models by up to 50% compared to systems using equivalent GPUs.

NASDAQ.COM
2.0
2025-12-01NASDAQ.COM
Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet
  • BioAtla Inc. Gains: BioAtla's shares surged 13.94% in after-hours trading, attributed to investor reactions to recent financing agreements, despite no new company-specific news.

  • Metagenomi Inc. and PAVmed Inc. Movements: Metagenomi's stock rose 5.71% with no new updates, while PAVmed advanced 5.72% after reporting a significant net loss and a sharp decline in revenue.

  • Precision BioSciences' Positive Outlook: Precision BioSciences gained 2.94% after announcing it will present Phase 1 trial data at an upcoming conference, boosting investor optimism.

  • Entero Therapeutics Rebranding: Entero Therapeutics' shares increased 3.68% following its announcement of a rebranding to GridAI Technologies Corp., effective December 1, 2025, along with a new ticker symbol.

Wall Street analysts forecast MGX stock price to rise
4 Analyst Rating
Wall Street analysts forecast MGX stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
7.00
Averages
8.67
High
12.00
Current: 0.000
sliders
Low
7.00
Averages
8.67
High
12.00
Chardan
Geulah Livshits
Buy
downgrade
$11 -> $7
AI Analysis
2025-11-12
Reason
Chardan
Geulah Livshits
Price Target
$11 -> $7
AI Analysis
2025-11-12
downgrade
Buy
Reason
Chardan analyst Geulah Livshits lowered the firm's price target on Metagenomi to $7 from $11 and keeps a Buy rating on the shares after the company reported Q3 results, announced the appointment of Dr. Jian Irish to CEO, and shared updated preclinical data on lead in vivo insertion program MGX-001 in hemophilia A. The firm updated its model for Q3 financials and removed the majority of platform value from the model in light of prioritization.
Chardan
downgrade
$12 -> $11
2025-08-15
Reason
Chardan
Price Target
$12 -> $11
2025-08-15
downgrade
Reason
Chardan lowered the firm's price target on Metagenomi to $11 from $12. The firm updated its model for Q2 financials and takes a slightly more conservative stance on programs/platform beyond hem A and the Ionis collaboration in light of the company's increasing focus on pipeline execution and advancing gene editing platform competition. The firm noted its Q2 adjustments shift its price target lower.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MGX
Unlock Now

Valuation Metrics

The current forward P/E ratio for Metagenomi Therapeutics Inc (MGX.O) is -0.67, compared to its 5-year average forward P/E of -1.29. For a more detailed relative valuation and DCF analysis to assess Metagenomi Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.29
Current PE
-0.67
Overvalued PE
-0.37
Undervalued PE
-2.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.28
Current EV/EBITDA
0.80
Overvalued EV/EBITDA
2.28
Undervalued EV/EBITDA
-1.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.89
Current PS
2.80
Overvalued PS
6.20
Undervalued PS
1.58

Financials

AI Analysis
Annual
Quarterly

Whales Holding MGX

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Metagenomi Therapeutics Inc (MGX) stock price today?

The current price of MGX is 1.51 USD — it has increased 2.03

What is Metagenomi Therapeutics Inc (MGX)'s business?

Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. It is developed to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. It focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. MGX-001, its lead, wholly owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. MGX-001 is designed to insert a Factor VIII (FVIII) DNA cassette into a safe harbor location within an intron of the albumin gene.

What is the price predicton of MGX Stock?

Wall Street analysts forecast MGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGX is8.67 USD with a low forecast of 7.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Metagenomi Therapeutics Inc (MGX)'s revenue for the last quarter?

Metagenomi Therapeutics Inc revenue for the last quarter amounts to 8.66M USD, decreased -24.80

What is Metagenomi Therapeutics Inc (MGX)'s earnings per share (EPS) for the last quarter?

Metagenomi Therapeutics Inc. EPS for the last quarter amounts to -0.55 USD, increased 7.84

How many employees does Metagenomi Therapeutics Inc (MGX). have?

Metagenomi Therapeutics Inc (MGX) has 202 emplpoyees as of March 17 2026.

What is Metagenomi Therapeutics Inc (MGX) market cap?

Today MGX has the market capitalization of 55.68M USD.